Media headlines about Pieris Pharmaceuticals (NASDAQ:PIRS) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Pieris Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.4735774056392 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:

PIRS has been the subject of several research analyst reports. Rodman & Renshaw initiated coverage on shares of Pieris Pharmaceuticals in a research note on Tuesday, May 30th. They issued a “buy” rating and a $9.00 price objective for the company. HC Wainwright set a $9.00 price objective on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 11th. BidaskClub downgraded shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 26th. Finally, TheStreet downgraded shares of Pieris Pharmaceuticals from a “c-” rating to a “d-” rating in a research note on Monday, June 12th. Five analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $8.25.

Shares of Pieris Pharmaceuticals (NASDAQ PIRS) opened at 5.43 on Tuesday. The stock’s 50 day moving average is $5.39 and its 200 day moving average is $4.93. Pieris Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $5.49. The firm’s market cap is $240.59 million.

In other Pieris Pharmaceuticals news, insider Allan Reine purchased 65,000 shares of the firm’s stock in a transaction dated Thursday, August 17th. The stock was acquired at an average cost of $4.82 per share, with a total value of $313,300.00. Following the acquisition, the insider now owns 45,000 shares of the company’s stock, valued at approximately $216,900. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director James A. Geraghty purchased 10,000 shares of the firm’s stock in a transaction dated Thursday, August 17th. The stock was acquired at an average cost of $4.82 per share, with a total value of $48,200.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $48,200. The disclosure for this purchase can be found here. Insiders own 4.05% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/19/pieris-pharmaceuticals-pirs-getting-somewhat-positive-news-coverage-study-finds.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Insider Buying and Selling by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.